Advertisement

Topics

Companies Related to "M7824 in Consensus Molecular Subtype 4, Treatment-Refractory Metastatic Colorectal Cancer" [Most Relevant Company Matches] RSS

19:14 EDT 21st September 2018 | BioPortfolio

Here are the most relevant search results for "M7824 in Consensus Molecular Subtype 4, Treatment-Refractory Metastatic Colorectal Cancer" found in our extensive corporate database of over 50,000 company records.

Showing "M7824 Consensus Molecular Subtype Treatment Refractory Metastatic Colorectal" Companies 1–25 of 4,300+

Extremely Relevant

Targeted Diagnostics and Therapeutics

TDT has emerged as a leader in the development of innovative molecular diagnostics and therapeutics that can improve the quality of life of patients with colorectal cancer and gastrointestinal malignancies. Focused on innovative research and cutting edge technology, TDT has developed highly specific tests to detect colorectal cancer cells in lymph nodes from patients who have undergone surgical st...


Relevant

Exact Sciences Corp.

Exact Sciences Corp. is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the ...

Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines ...


Targeted Diagnostics & Therapeutics, Inc

TDT has emerged as a leader in the development of innovative molecular diagnostics and therapeutics that can improve the quality of life of patients with colorectal cancer and gastrointestinal malignancies. Focused on innovative research and cutting edge technology, TDT has developed highly specific tests to detect colorectal cancer cells in lymph nodes from patients who have undergone surgical st...

DACOGEN

DACOGEN is indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and i...

Colonix Medical Limited

Colonix Medical Limited has pioneered and refined a new system for the early detection / screening of colorectal cancer and other bowel diseases such as IBD. This system can be used for both symptomatic and non symptomatic patients. Colorectal cancer is often referred to as ‘the silent killer’. If detected early, colorectal cancer treatments are effective and after treatment most sufferers ca...

Biothera Pharmaceuticals, Inc.

Biothera is a privately held biotechnology company developing Imprime PGG, a clinical stage immunotherapy drug that modulates key immune cells to orchestrate a coordinated immune response to cancer that involves both the innate and adaptive immune system. Proof of concept has been established from single-arm and randomized phase 2 studies in non-small cell...

SolaranRx, Inc.

SolaranRx, Inc. is developing a platform of new therapies and companion imaging agents for the treatment of metastatic melanoma. This merger between therapeutics and diagnostics—often referred to as theranostics—constitutes a new level of personalized medicine for treating metastatic melanoma. SolaranRx seeks to improve treatment and patientsâ€...

bioTheranostics, Inc.

bioTheranostics discovers, develops, and commercializes a growing array of molecular diagnostic tests for cancer patients. Leveraging its unique expertise in expression profiling and algorithm development, bioTheranostics is well positioned to be a partner and solution provider in metastatic cancer. The company operates a CLIA-certified, CAP-accredited dia...

Biothera Pharmaceutical Inc.

Biothera is a privately held biotechnology company developing Imprime PGG, a late clinical stage immunotherapeutic drug candidate that modulates key immune cells to recognize and kill cancer. Proof of concept has been established from single-arm and randomized Phase 2 studies in non-small cell lung cancer (NSCLC), colorectal cancer, and chronic lymp...

Foundation Medicine, Inc.

Foundation Medicine (NASDAQ: FMI) is a molecular information company focused on fundamentally changing the way patients with cancer are treated. Our proprietary molecular information platform generates actionable genomic information about a patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and enabling biopharmaceutical companies to develop target...

MetaStat, Inc.

MetaStat, Inc (OTCQB:MTST) is a molecular diagnostic company that develops and commercializes diagnostic tests for early and reliable prediction of systemic metastasis, the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body. MetaStat is focused on breast, prostate, lung and colorectal cancers, where syst...

Biothera

Biothera, a privately held U.S. biotechnology company, is developing Imprime PGG, a late clinical stage biologic that modulates the immune response to cancer. Data from the most recent randomized phase 2 study of Imprime PGG in first line non-squamous non-small cell lung cancer (NSCLC) was featured as a late-breaking abstract in the Immunotherapy of Cancer...

Dendreon Corporation

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates de...

Colorectal Cancer Coalition

This critical legislation will ensure that even in tight fiscal times, funding for life-saving federal colorectal cancer research programs can be sustained.

Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer. We are currently focusing our development efforts on picoplatin, a new generation platinum therapy that provides a differentiated spectrum of activity and an improved safety profile. An intravenous chem...

Plexxikon Inc.

Plexxikon is a leader in the structure-guided discovery and development of novel small molecule pharmaceuticals to treat human disease. The company’s lead compound, PLX4032, is in late-stage clinical trials for the treatment of melanoma. Other clinical-stage programs include PLX5568 for the treatment of polycystic kidney disease, PLX204 for the treatment ...

Cancer Commons

Cancer Commons is a non‐profit open science initiative dedicated to improving outcomes for today’s cancer patients. Our goals are to: 1) give each patient the best possible outcome by individualizing their treatment based on their tumor’s genomic subtype; 2) learn as much as possible from each patient’s response, and 3) rapidly disseminate wha...

WILEX AG

WILEX is a biopharmaceutical company developing novel cancer therapies for the treatment of various tumors including renal and breast cancer. Therapies are based upon biologic targets directly connected to cancer progression and pathogenesis in order to provide effective and well-tolerated treatment and enhance patients' quality of life.The company has a portfolio of cancer drug candidates ranging...

Bandaid Surgery, PC

Laparoscopic colon surgery, also known as band-aid colon surgery, is a revolutionary colorectal surgical technique pioneered and perfected by Dr.David Blumberg, a Board Certified General and Colorectal Surgeon while in the Department of Surgery at the University of Pittsburgh Medical Center. Company Overview: Band-aid colon surgery is a revolutionary colorectal surgical technique pioneered...

Coronado Biosciences, Inc.

Coronado Biosciences, Inc. is a private, clinical stage company that is focused on the development of therapeutic products for the treatment of cancer. Coronado has three programs; cndo102 activated NK cells for the treatment of relapsed/refractory AML, cndo101, a 4th generation doxorubicin analogue for the treatment of women with breast cancer who have the CAP17 duplication, and C1, a pan Bcl-2 ...

A&G Pharmaceutical Incorporated

A&G Pharmaceutical, Inc. (A&G) was incorporated in Delaware on June 6, 2000, as a "C" Corporation, to make use of two proprietary technologies that are unique to the Company. A&G is located in Baltimore, Maryland, and consists of two distinct but integrate divisions: 1) the Pharmaceutical Division and 2) the Monoclonal Antibody Services Division. Pharmaceutical Division Breast cancer is the most ...

Report Card Coalition

Launched in 2004, the Colorectal Cancer Legislation Report Card initiative is supported by a coalition that includes American Cancer Society Cancer Action Network, American College of Gastroenterology, American Gastroenterological Association, American Society of Colon and Rectal Surgeons, American Society for Gastrointestinal Endoscopy, the Cancer Support Community, C3: Colorectal Cancer Coalitio...

Delcath Systems, Inc.

Delcath Systems, Inc. is a development stage, specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of pri...

Molecular Insight Pharmaceuticals

Molecular Insight Pharmaceuticals, Inc. is focused on the research, development and commercialization of innovative molecular imaging pharmaceuticals and targeted radiotherapeutics to diagnose, treat and manage disease. The company's two lead compounds, Zemivaâ„¢ and Azedraâ„¢, are in advancing clinical programs. Molecular Insight has completed a Phase 2b clinical trial for its lead cardio...


More From BioPortfolio on "M7824 in Consensus Molecular Subtype 4, Treatment-Refractory Metastatic Colorectal Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks